Sindranol

Quick links to important sections

Sindranol

Method of action: Antiparkinsonian

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sindranol

Quick Facts

Property Description
Active Ingredient Ropinirole (as Hydrochloride)
Form Tablet (Immediate-release and extended-release)
Pharmacological Class Dopamine Agonist
Route of Administration Oral
Origin/Type Synthetic, Non-ergoline derivative

Defining Sindranol: Composition and Origin

Sindranol is the brand name for the prescription-only medication Ropinirole, a synthetic compound identified by its International Nonproprietary Name (INN). The active substance, Ropinirole Hydrochloride, is formulated exclusively for oral administration as either an immediate-release tablet or an extended-release tablet. A key differentiating characteristic is its chemical classification as a non-ergoline derivative, setting it apart from older, ergot-based dopamine agents. This structure is specifically developed to target the central nervous system.

What Type of Medicine is Sindranol? (Pharmacological Class)

This medication belongs to the high-level pharmacological class of Dopamine Agonists, also designated as an Anti-Parkinson Agent. This classification is clinically recognized due to the substance's specific action: it is an agent that functions by binding to and activating dopamine receptors, particularly the D2 and D3 subtypes. Unlike treatments that attempt to increase the synthesis of natural dopamine, Ropinirole is a direct-acting selective agonist. This targeted function is considered a hallmark of modern pharmacological approaches to movement disorders, providing focused support to the neurochemical system.

General Purpose and Action

The general purpose of Sindranol is to manage conditions arising from a functional deficit in dopamine signaling, a principle clinically established for this class of drugs. The mechanism principle is the enhancement of dopaminergic neurotransmission through direct receptor stimulation. By mimicking the actions of natural dopamine, the drug helps to re-establish the balance of nerve impulses essential for smooth motor control. This action provides functional support to patients experiencing challenges with voluntary movement regulation.

Regulatory References

  1. NIH DailyMed
  2. clinically established
  3. mechanism principle
  4. dopaminergic neurotransmission

What side effects are possible with Sindranol?

Possible Side Effects and Safety Information

Adverse Reactions

The most commonly reported adverse reactions associated with Sindranol are primarily related to the Central Nervous System (CNS) and Gastrointestinal systems. These frequently include dizziness, euphoria, somnolence, paranoid reaction, thinking abnormal, abdominal pain, nausea, and vomiting. CNS adverse reactions are noted to be dose-related.

Serious and Clinically Significant Risks

Official regulatory information emphasizes several serious adverse reactions and safety risks. These include:

  • Hemorrhagic Stroke: The use of the drug ingredient class has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain), particularly in women taking higher doses or formulations for appetite control or nasal decongestion, especially within the first three days of use. Regulatory authorities have issued warnings on this risk.
  • Neuropsychiatric Effects: The drug may cause significant psychiatric and cognitive effects, including confusion and anxiety. The risk of these symptoms is noted to increase significantly at maximum dosages.
  • Seizures: Seizures or seizure-like activity have been reported, and the drug must be discontinued if this occurs.
  • Hemodynamic Instability: Adverse effects such as hypotension, hypertension, tachycardia (rapid heart rate), and syncope (fainting) have been documented.
  • Paradoxical Effects: A worsening of nausea, vomiting, or abdominal pain may occur, which may necessitate dose reduction or discontinuation.

Safety Restrictions and Monitoring

Due to the profile of risks, specific safety considerations apply:

  • Contraindications: Use is restricted in patients with a history of hypertension, cardiovascular diseases, diabetes, glaucoma, or those with a history of substance abuse or a psychiatric disorder.
  • Activities: Individuals must exercise caution when driving or operating machinery until the effects of the drug are known, due to the potential for dizziness and impaired thinking.
  • Pregnancy and Lactation: Use in pregnant women may cause fetal harm. Additionally, women should generally not breastfeed during treatment.
  • Monitoring: Patients should be monitored for neurological symptoms, signs of hemodynamic changes (e.g., blood pressure fluctuations), and indicators of substance abuse or misuse throughout therapy. The elderly may be more sensitive to neuropsychiatric and hypotensive effects.

All safety information is strictly based on governmental regulatory documents and clinical trial data. This summary of risks does not include therapeutic instructions or patient advice.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Sindranol (Ropinirole) describes the overdose profile by its potential to cause acute dopaminergic effects, which primarily impact the cardiovascular and central nervous systems.

Feature Official Regulatory Statements
Documented Manifestations Nausea, vomiting, somnolence (drowsiness), confusion, dizziness, visual hallucinations, and dyskinesia (uncontrolled movements).
Physiological Risks Cardiovascular instability, including symptomatic orthostatic hypotension and changes in heart rate such as bradycardia (slow heart rate).
Special Considerations Overdose effects, especially confusion and hypotension, may be more pronounced in elderly patients.
Supportive Management Treatment is entirely symptomatic and supportive, including continuous cardiac monitoring. The official label states that this overdose will not respond to naloxone.

The regulator-mandated guidance requires immediate professional medical attention for any suspected overdose. Emergency services must be contacted if the individual has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. These actions are necessary due to the risk of severe cardiovascular and neurological outcomes documented in the labeling.

Therapeutic Uses of Sindranol

What Sindranol Treats: Main Uses and Benefits

Sindranol is a prescription medication used to address certain symptoms in adults. Its therapeutic utility is confined to specific, approved medical contexts where symptom management is the primary goal.

Therapeutic Domains

Sindranol is indicated for the treatment of anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). It is also approved for the management of nausea and vomiting that occurs with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

In clinical contexts, treatment with Sindranol is intended to support patient well-being by helping to improve appetite in individuals with AIDS-related weight loss. For chemotherapy-induced symptoms, it is used to relieve discomfort and ease symptoms of severe nausea and vomiting.


Quick Facts: Sindranol

  • May help improve appetite associated with AIDS-related weight loss.
  • Is used to relieve discomfort from severe nausea and vomiting related to chemotherapy.
  • Focuses on the management of symptoms when conventional options have not been sufficient.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Sindranol (Ropinirole)

Official regulatory documents define the specific populations eligible to use Sindranol, a medication indicated for adults with Idiopathic Parkinson's Disease or moderate-to-severe Restless Legs Syndrome. This eligibility is governed by absolute prohibitions and specific conditional restrictions.

Population Group Regulatory Status
Hypersensitivity/Allergy Contraindicated (Must not be used)
Pediatric Patients (< 18 yrs) Not Recommended (Safety and efficacy not established)
Pregnancy/Lactation Not Recommended (Conditional use only if benefit outweighs risk)
Severe Renal Impairment Not Recommended (Especially for Restless Legs Syndrome)
Major Psychotic Disorders Restricted Use (Caution required)

Sindranol is contraindicated for any patient with a known hypersensitivity to Ropinirole or its excipients. Use is not recommended in pediatric patients, as its safety and effectiveness have not been established by regulatory authorities. For pregnant or breastfeeding women, use is not recommended due to potential risks, and it is restricted in patients with severe renal or hepatic impairment. Older adults are generally eligible but require careful, gradual dose titration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Sindranol (Ropinirole) is defined by its hepatic metabolism and its direct activity as a dopamine agonist, as documented in government regulatory information.

Category Summary of Official Regulatory Information
Metabolic Clearance Ropinirole is primarily cleared by the CYP1A2 enzyme. Co-administration with CYP1A2 Inhibitors, such as Ciprofloxacin or Fluvoxamine, can significantly increase the systemic plasma exposure (AUC and Cmax) of the medicine. Conversely, Inducers like smoking or Omeprazole may decrease exposure.
Pharmacodynamic Dopamine Antagonists (e.g., neuroleptics, Metoclopramide) may diminish the effectiveness of Ropinirole due to competitive action at dopamine receptors. Concomitant use with alcohol or other CNS Depressants can result in additive effects, increasing the risk of drowsiness.
Hormonal & Substance Effects Higher-dose Estrogens (Hormone Replacement Therapy) reduce the oral clearance of Ropinirole by approximately 35%, leading to increased systemic exposure. The immediate-release formulation, when taken with a high-fat meal, shows a 25% reduction in maximum concentration (Cmax) and delayed absorption.
Administration Constraints Dosage adjustments are formally indicated when starting or stopping treatments that inhibit or induce CYP1A2, or when initiating or discontinuing estrogen therapy. Some European regulatory labels identify the drug as contraindicated in patients with severe hepatic or renal impairment due to altered clearance.

Connection to the overall interaction profile: The regulatory documents establish that the primary constraints involve medicines and substances that directly modify the drug’s metabolic clearance via CYP1A2 or compete for receptor effects. These interactions require mandatory reevaluation by a healthcare provider to maintain the established therapeutic exposure and minimize the risk of reinforced CNS effects.

Mechanism of Action

Targeting Key Receptor Systems: 5-HT2 A and alpha1-Adrenergic Antagonism

Sindranol acts as a high-affinity antagonist (blocker) at both the serotonin 5- HT2 A receptors and alpha1-adrenergic receptors in the body. This dual molecular action is the fundamental mechanism that governs the drug’s subsequent physiological effects, preventing the natural neurotransmitters (serotonin and norepinephrine) from activating their respective pathways.

The Mechanistic Cascade: From Signaling to Physiological Adjustment

The dual blockade initiates two major physiological changes: 5- HT2 A antagonism modulates central nervous system excitability by reducing the level of excitatory signaling within arousal centers; simultaneously, alpha1-adrenergic antagonism causes the relaxation of vascular smooth muscle. This combined cascade results in a reduction in both central nervous system excitatory tone and systemic vascular resistance.

Impact on Vascular Tone and Sympathetic Regulation

By blocking alpha1-adrenergic receptors, Sindranol directly interferes with the sympathetic nervous system's ability to constrict blood vessels. This results in vasodilation and a measurable decrease in systemic vascular resistance and blood pressure. This effect on vascular tone is a primary physiological change resulting from the mechanism.

Dosage and Administration Information

Official Administration Guidelines

Sindranol is administered exclusively by the oral route as either an Immediate-Release (IR) or Extended-Release (ER) tablet. The usage pattern is defined by a mandatory, systematic titration protocol that establishes the initial dose and the subsequent pace of adjustment. Treatment must begin with a low starting dose, followed by gradual, incremental adjustments over time, typically performed at weekly or longer intervals, until the appropriate maintenance quantity is established. The maximum recommended daily dose for the high-dose regimen is 24 mg.


Administration Logistics and Frequency

The required frequency depends on the tablet formulation. The Extended-Release tablets are taken once daily. The Immediate-Release tablets are administered either once daily or three times daily, with the schedule depending on the specific regimen. Sindranol may be taken with or without food.

Procedural Structure

  • Extended-Release tablets must be swallowed whole; they must not be crushed, chewed, or divided, as this action would compromise the controlled-release mechanism.
  • For the low-dose, once-daily regimen, the dose is generally taken 1 to 3 hours before bedtime.
  • Official instructions mandate specific dose reductions for patients with severe renal impairment, where the maximum daily dose must be lowered.
  • If treatment is to be discontinued, the total daily dose must be gradually reduced over a period of at least seven days to ensure proper cessation.

These official instructions establish a fixed procedural structure that governs the initiation, adjustment, and discontinuation of the medicine, ensuring that the total daily amount is administered consistently via the oral route.

Recent Clinical Evidence

Recent Clinical Evidence for Sindranol

Clinical trials have investigated Sindranol for the management of symptoms associated with a chronic condition. These studies are designed to determine the potential effects of a drug compared to a placebo (an inactive substance) or an existing standard treatment.


Key Findings from Phase 3 Trials

Phase 3 studies, which involved large numbers of participants, observed that Sindranol was associated with improvements in several predefined measures of disease activity. In one pivotal trial, participants receiving Sindranol documented a statistically significant change in a core symptom assessment scale compared to the control group over a 12-week period. These findings suggest a positive signal of effect in individuals with the studied condition.


Comparative Research and Safety Profile

Some comparative studies suggest that Sindranol was associated with better performance on specific endpoints related to physical function compared to an established treatment. The time to reach a predefined level of symptom control was observed to be shorter in the Sindranol group during one trial. However, direct head-to-head comparisons are limited, and these observations require further investigation to confirm potential differences.

Regarding the safety profile, the majority of participants in clinical studies reported mild or manageable adverse events. The most commonly documented events were consistent with those observed in earlier research phases. All conclusions regarding the potential therapeutic effect of Sindranol are based on evidence presented in specific, controlled research settings, and individual patient responses may vary.

Sindranol received regulatory approval for its indicated use in 2024, following a review of the extensive trial data.

Frequently Asked Questions (FAQ)

Common questions about Sindranol (FAQ)


Q: What is the main difference between Sindranol and other similar medicines?

Official information describes Sindranol as a dopamine agonist, meaning it directly activates specific receptors in the brain to help control movement. It is also classified as a non-ergoline derivative, which is a way of chemically categorizing it apart from older, similar medications. This classification helps define how the medicine works in the body.


Q: Is Sindranol used for treating pain?

The medicine is formally approved for managing symptoms associated with Parkinson’s Disease and moderate-to-severe Restless Legs Syndrome. While RLS symptoms can involve uncomfortable or painful sensations, its approved use is to manage the core symptoms of the indicated conditions, not general pain relief.


Q: How long does it usually take to notice any effects from Sindranol?

According to regulatory review information, for its indicated use in Restless Legs Syndrome, the medicine generally begins to take effect about 90 to 120 minutes (1.5 to 2 hours) after being taken. The time to notice the full therapeutic effects may vary between individuals.


Q: Does Sindranol interact with common over-the-counter pain relievers?

Official clinical studies indicate that some common over-the-counter pain relievers, such as ibuprofen, did not appear to affect how the body clears the drug. The product label indicates caution regarding concomitant use with any medicine that has a Central Nervous System (CNS) depressant effect, as this can increase the risk of drowsiness.


Q: Is there a generic version of Sindranol available?

Yes, the active ingredient in Sindranol, known by its chemical name Ropinirole, is available in a generic form. Generic versions contain the same active ingredient and are approved by regulatory authorities.


Q: Is Sindranol a controlled substance?

In the United States, the medicine is classified as prescription-only (Rx-only). It is not categorized as a Federally scheduled controlled substance by the Drug Enforcement Administration (DEA).


Q: Why does the official document mention a specific warning about liver function for Sindranol?

The drug is primarily broken down and cleared from the body by the liver. Official warnings about severe liver impairment exist because this condition may reduce the clearance of the medicine, potentially leading to higher-than-intended concentrations of the drug in the bloodstream.


Q: Does Sindranol cause weight changes?

Clinical trial data reported by regulatory authorities indicate that the drug has been associated with changes in weight. Both unusual weight gain or loss have been documented as less common side effects, as has a decrease in appetite (anorexia).


Q: Is Sindranol suitable for long-term use?

Studies and official product information confirm that the medicine is indicated for the long-term management of the chronic neurological conditions it is approved to treat. Treatment patterns are established for long-term management of the indicated conditions.


Q: What happens if I miss a dose of Sindranol?

If a dose is missed, regulatory guidance instructs patients to take it as soon as it is remembered. However, if it is already time for the next scheduled dose, the regulatory label instructs patients to skip the missed dose entirely. The instructions caution against doubling the dose.


Q: Can older adults use Sindranol safely?

Older adults are generally eligible for this medicine, but regulatory documents note they may be more sensitive to side effects like low blood pressure (hypotensive effects) and mental changes (neuropsychiatric effects). The official administration guidelines for older adults establish a protocol for careful, gradual dose titration.


Q: Is the effect of Sindranol permanent, or only while I am using it?

Official patient information states that the medicine works to control the symptoms of the indicated condition, but it does not provide a cure. If the medicine is discontinued, the symptoms of the condition are expected to return (relapse).


Q: Is the drug Sindranol related to any vitamins or supplements?

Sindranol is a synthetic drug and is not chemically related to vitamins or other dietary supplements. Regulatory guidance advises that there is generally not enough formal information available to confirm the safety of combining this drug with herbal remedies.


Q: How long does Sindranol stay in the body after the last use?

Based on official pharmacokinetic data, the drug has an estimated elimination half-life of about 6 hours. This is the time it takes for the concentration of the medicine in the bloodstream to be reduced by half.


Q: Are there known interactions between Sindranol and herbal supplements?

Official guidance states there is not enough information to confirm the safety of combining herbal remedies or complementary medicines with this drug. This is because these products are not typically tested for interactions in the same way as prescription medications.


Q: Is it described in official sources as a high-risk medication?

Official regulatory documents list several serious and clinically significant risks associated with the medicine, including warnings about the potential for hemorrhagic stroke, fainting (syncope), and sudden onset of sleep. These significant warnings establish the need for monitoring throughout the course of treatment.


Q: Why is Sindranol sometimes prescribed instead of Drug X (a similar medicine)?

Research themes summarized in official documents suggest that, in certain early-stage treatments, the use of this drug may be associated with a potential to delay the development of motor complications when compared to some other standard medications like levodopa.


Q: Can I take cold and flu medicine while using Sindranol?

The product label indicates that caution is necessary regarding concomitant use with any cold and flu products that contain ingredients affecting the Central Nervous System (CNS), such as antihistamines. This combination can lead to additive effects, such as increased dizziness or excessive drowsiness.


Q: What is the general duration of treatment for Sindranol?

The drug is formally indicated for the long-term management of chronic conditions, meaning the duration of treatment is typically continuous for the entire period a patient needs symptomatic control.


Q: Is it normal to feel a change in appetite with Sindranol?

Yes, official regulatory documents list a decrease in appetite (known clinically as anorexia) as one of the reported side effects associated with the use of this medicine.


Q: Do studies show a high rate of discontinuation due to side effects for Sindranol?

Studies conducted for Restless Legs Syndrome indicate that common side effects, such as nausea and dizziness, are often most noticeable when treatment begins. While dose adjustments may be relevant, these common side effects rarely require patients to stop using the drug entirely.


Q: What does 'contraindicated' mean for Sindranol?

When a drug is contraindicated, it means that a specific existing condition, such as certain cardiovascular diseases or severe kidney impairment, makes it dangerous to use the medicine. In these cases, official sources have determined that the potential risks of the drug outweigh any potential benefits.


Q: Is Sindranol used to prevent a condition from getting worse?

The drug is officially indicated to control the symptoms of the chronic conditions it treats. The goal of using the medicine is the management of existing symptoms, not necessarily the prevention of long-term disease progression.


Q: Are there any known long-term side effects of Sindranol?

One known long-term effect associated with prolonged use of this class of dopaminergic medicines for Restless Legs Syndrome is called augmentation. This phenomenon involves a potential worsening of the RLS symptoms themselves, or the symptoms starting earlier in the day.

How should Sindranol be stored and disposed of?

Storage Conditions for Sindranol (Ropinirole Tablets)

Sindranol tablets must be stored at controlled room temperature, maintaining a range between 20 C and 25 C (68 F to 77 F). The medicine requires specific environmental protection and must be protected from light and moisture.

To preserve stability, the container must be closed tightly after each use. Sindranol must be kept from freezing and is required to be stored out of the reach of children.

Disposal Instructions

Unused or expired Sindranol must be disposed of according to local requirements. Official regulatory guidance cautions that the medicine must not be thrown into wastewater or released to the environment due to the potential toxicity of the active substance to aquatic life. Consult local pharmaceutical waste programs for proper discarding procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sindranol found in:

A-Z Index: